Today: 8 June 2026
Browse Category

NYSE:KMB 19 December 2025 - 25 January 2026

Kenvue stock steadies near $18 as investors eye Jan. 29 merger vote — here’s what matters next week

Kenvue stock steadies near $18 as investors eye Jan. 29 merger vote — here’s what matters next week

Kenvue closed Friday at $17.80, up 0.3%, ahead of a merger vote with Kimberly-Clark set for Jan. 29. The deal values Kenvue shares at about $18.45, but ongoing shareholder lawsuits and unresolved litigation over Kenvue brands threaten delays. Proxy advisers back the deal despite legal risks. Both companies hold shareholder meetings Monday to decide the merger’s fate.
25 January 2026
··
Kenvue (KVUE) stock price barely budges as Kimberly-Clark deal vote nears

Kenvue (KVUE) stock price barely budges as Kimberly-Clark deal vote nears

Kenvue shares rose 0.1% to $17.77 Friday as investors await a Jan. 29 shareholder vote on its proposed sale to Kimberly-Clark. The deal would give Kenvue holders $3.50 in cash and 0.14625 Kimberly-Clark shares per Kenvue share. Institutional Shareholder Services recommended approval but cited litigation risks. Trading volume has surged ahead of the vote.
23 January 2026
···
Kenvue stock ticks up as investors size up Kimberly-Clark takeover vote in days

Kenvue stock ticks up as investors size up Kimberly-Clark takeover vote in days

Kenvue shares rose 0.6% to $17.31 in late-morning New York trading Tuesday as investors awaited a Jan. 29 shareholder vote on its proposed sale to Kimberly-Clark. The deal’s outcome remains uncertain amid ongoing litigation risks tied to Kenvue’s legacy products. ISS has backed the merger but flagged legal concerns. Kenvue’s virtual shareholder meeting is scheduled for 9:00 a.m. Eastern on Jan. 29.
20 January 2026
··
Johnson & Johnson stock heads into earnings after a mild dip — what could move JNJ next

Johnson & Johnson stock heads into earnings after a mild dip — what could move JNJ next

Johnson & Johnson shares closed down 0.4% at $218.66 Friday ahead of the Martin Luther King Jr. Day market holiday. The S&P 500 health care sector fell 0.8%. J&J reports fourth-quarter results Wednesday, Jan. 21, with investors focused on earnings and 2026 guidance. The NYSE will reopen Tuesday after the holiday.
18 January 2026
·······
Kenvue stock has a new catalyst: ISS backs Kimberly-Clark merger ahead of Jan. 29 vote

Kenvue stock has a new catalyst: ISS backs Kimberly-Clark merger ahead of Jan. 29 vote

Kenvue shares closed at $17.20 Friday, down 0.35%, ahead of a Jan. 29 shareholder vote on its sale to Kimberly-Clark. Proxy adviser ISS recommended investors back the deal but cited ongoing legal and market risks. Kenvue updated merger disclosures after lawsuits challenged the process. The offer values Kenvue at about $18.03 per share, a 4.6% premium to Friday’s close.
18 January 2026
··
Kenvue stock edges up as Kimberly-Clark vote nears — the deal spread traders are watching

Kenvue stock edges up as Kimberly-Clark vote nears — the deal spread traders are watching

Kenvue shares rose 0.4% to $17.08 in mid-morning trading after Kimberly-Clark filed new deal documents with U.S. regulators. The stock remains about 5% below the value implied by the pending cash-and-stock takeover. Kenvue shareholders are set to vote on the deal Jan. 29. The transaction’s value fluctuates with Kimberly-Clark’s share price.
14 January 2026
···
Kenvue (KVUE) stock nudges up as fresh deal scrutiny hits — and the spread traders are watching

Kenvue (KVUE) stock nudges up as fresh deal scrutiny hits — and the spread traders are watching

Kenvue shares rose 0.8% to $16.87 Thursday after law firm Kahn Swick & Foti said it is investigating the company’s pending sale to Kimberly-Clark. The offer values Kenvue at about $17.91 per share, a 6% premium to Thursday’s price. Shareholders are set to vote on the deal in late January. Kenvue also named Madhav Nayak as vice president and chief marketing officer for Asia-Pacific.
8 January 2026
··
Kenvue Stock (NYSE: KVUE) News Today: Kimberly-Clark Deal Update, Insider Buying, Analyst Forecasts — December 25, 2025

Kenvue Stock (NYSE: KVUE) News Today: Kimberly-Clark Deal Update, Insider Buying, Analyst Forecasts — December 25, 2025

Kenvue shares closed December 24 at $17.21, up 1.12% in light holiday trading, as investors weigh Kimberly-Clark’s pending acquisition. The agreed deal values KVUE at about $18.28 per share based on current KMB prices, but the stock trades below that level amid regulatory, timing, and legal uncertainties. The transaction is expected to close in the second half of 2026.
25 December 2025
··
Kenvue Stock (KVUE) News, Forecasts and Analysis for December 23, 2025: Deal Math, Legal Headlines, and What Investors Are Watching

Kenvue Stock (KVUE) News, Forecasts and Analysis for December 23, 2025: Deal Math, Legal Headlines, and What Investors Are Watching

A Baltimore jury ordered Johnson & Johnson and spinoff Kenvue to pay over $1.5 billion in a talc cancer case, with J&J saying it will appeal. Kenvue shares traded at $16.98, about $1.15 below the implied $18.12 merger value based on Kimberly-Clark’s price, reflecting deal risk. The acquisition is expected to close in the second half of 2026. J&J has said it will cover Kenvue’s talc liabilities.
23 December 2025
···
Kenvue Stock (KVUE) News Today: Deal Spread Math, Kimberly-Clark Vote Timeline, Tylenol Lawsuits, and Analyst Forecasts (Dec. 19, 2025)

Kenvue Stock (KVUE) News Today: Deal Spread Math, Kimberly-Clark Vote Timeline, Tylenol Lawsuits, and Analyst Forecasts (Dec. 19, 2025)

Kenvue shares closed at $17.10 on Dec. 19, 2025, down 1.04% amid heavy trading. Kimberly-Clark’s pending cash-and-stock acquisition values Kenvue at about $18.35 per share, based on current prices, leaving a deal spread of roughly 7%. The merger awaits shareholder and regulatory approval, with legal risks and earnings pressure influencing the stock.
19 December 2025
··
1 2 3

Stock Market Today

  • Stock Market Update: Dow Expected to Weaken, Nasdaq to Gain After Sharp Dip; Oil Prices Surge Amid Middle East Conflict
    June 8, 2026, 9:06 AM EDT. The Dow Jones Industrial Average is set to weaken while the Nasdaq Composite is poised for gains after the S&P 500 experienced its worst day since October. This downturn follows renewed violence in the Middle East, with Iran striking Israel, escalating geopolitical tensions. Oil prices jumped significantly, reflecting concerns over supply disruptions linked to the conflict. Investors remain cautious as markets digest the impact of escalating regional instability on global economic outlooks.

Latest articles

Plug Power Stock Faces a Make-or-Break Week After Friday’s 10% Drop

Plug Power Stock Faces a Make-or-Break Week After Friday’s 10% Drop

8 June 2026
Plug Power rose 2.95% to $3.31 in Monday pre-market trading after a $39.2 million federal tax credit sale tied to its St. Gabriel hydrogen facility, as investors await CEO Jose Luis Crespo’s June 11 update on liquidity and asset sales amid ongoing losses and a recent 10.69% stock drop.
ABAT Shares Jump on DOE’s $115M Lithium Grant Return

ABAT Shares Jump on DOE’s $115M Lithium Grant Return

8 June 2026
American Battery Technology Co shares soared 29.58% to $4.03 premarket after the U.S. Department of Energy fully reinstated a $115 million grant for its Nevada lithium refinery, restoring federal funding for the Tonopah Flats Lithium Project with no change to awarded funds or milestones, though risks remain from permitting, financing, and volatile lithium prices.
NANO Nuclear Stock Bounces, Investors Eye What’s Next

NANO Nuclear Stock Bounces, Investors Eye What’s Next

8 June 2026
NANO Nuclear Energy jumped 7.8% to $25.40 in premarket trading after a 9.9% Friday drop, as traders weighed fresh insider sales filings and recent regulatory progress on its KRONOS microreactor project; the company held $568.7 million in cash as of March 31, but faces sector-wide volatility and execution risks.
Nurix Shares Jump Premarket on Roche $2.3 Billion Cancer Drug Deal

Nurix Shares Jump Premarket on Roche $2.3 Billion Cancer Drug Deal

8 June 2026
Nurix soared 20.4% to $17.62 premarket after Roche agreed to pay $700 million up front in a bexobrutideg collaboration worth up to $2.3 billion, a major cash boost and external validation for Nurix’s lead blood cancer drug ahead of a planned Phase 3 trial, with Roche’s clinical and commercial backing now in play.
Go toTop